Joseph Markowitz, Alexander D. MacKerell and David J. Weber Pages 609 - 616 ( 8 )
Typically, malignant melanoma has wild-type p53, and yet this cancer proliferates. S100B, which binds p53 and is up-regulated in melanoma, down-regulates wild-type p53 tumor suppressor function. Inhibitors of the S100B-p53 interaction were identified using computer aided drug design (CADD) combined with NMR methodologies and represent potentially new chemotherapeutics for melanoma.
S100B, p53, calcium, inhibitors, drug design, cancer
Dept. of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N.Greene St., Baltimore, MD 21201, USA.